Volume 28, Number 6—June 2022
Dispatch
Rapid Increase of Community SARS-CoV-2 Seroprevalence during Second Wave of COVID-19, Yaoundé, Cameroon
Table 2
Characteristic | Participants, survey 1, January 27–February 6 |
Participants, survey 2, April 24–May 19 |
|||||||
---|---|---|---|---|---|---|---|---|---|
Total no. | No. (%) positive | % Positive (95% CI) | p value | Total no. | No. (%) positive | % Positive (95% CI) | p value | ||
Age group, y | 0.002 | <0.001 | |||||||
0–19 | 236 | 31 | 13.1 (9.3–18.3) | 468 | 200 | 42.7 (38.3–47.3) | |||
20–39 | 276 | 71 | 25.7 (20.8–31.4) | 440 | 263 | 59.8 (55.0–64.4) | |||
>40 |
210 |
48 |
22.9 (17.5–29.2) |
320 |
201 |
62.8 (57.3–68.0) |
|||
Sex | 0.773 | 0.942 | |||||||
F | 423 | 89 | 18.5 (14.8–22.9) | 718 | 392 | 51.0 (47.1–54.8) | |||
M |
299 |
61 |
19.0 (14.8–24.1) |
510 |
272 |
51.6 (47.0–56.1) |
|||
No. symptoms | 0.688 | 0.288 | |||||||
0 | 271 | 70 | 22.5 (17.8–28.0) | 776 | 424 | 51.8 (48.1–55.5) | |||
1–2 | 157 | 26 | 12.8 (7.5–21.0) | 257 | 129 | 47.8 (41.6–54.0) | |||
3–5 | 134 | 27 | 22.5 (13.5–35.2) | 167 | 92 | 53.9 (45.6–61.9) | |||
>5 |
68 |
17 |
18.4 (8.4–35.9) |
28 |
19 |
57.5 (39.0–75.7) |
|||
Hospitalization | 0.150 | 0.487 | |||||||
Yes | 28 | 6 | 10.7 (4.4–23.6) | 12 | 8 | 51.0 (17.3–83.9) | |||
No |
329 |
64 |
18.0 (12.8–24.7) |
445 |
229 |
50.1 (45.1–55.2) |
|||
Total | 722 | 150 | 18.6 (15.7–21.7) | 1 228 | 664 | 51.3 (48.3–54.2) |
*Overall seroprevalence estimate was age-standardized, based on available demographic data (12).
References
- World Health Organization. Coronavirus (COVID-19) dashboard [cited 2021 Nov 26]. https://covid19.who.int
- Africa Centres for Disease Control and Prevention. Coronavirus disease 2019 (COVID-19) [cited 2021 Nov 26]. https://africacdc.org/covid-19
- Chisale MRO, Ramazanu S, Mwale SE, Kumwenda P, Chipeta M, Kaminga AC, et al. Seroprevalence of anti-SARS-CoV-2 antibodies in Africa: A systematic review and meta-analysis. Rev Med Virol. 2022;32:
e2271 . DOIPubMedGoogle Scholar - Sagara I, Woodford J, Kone M, Assadou MH, Katile A, Attaher O, et al. Rapidly increasing SARS-CoV-2 seroprevalence and limited clinical disease in three Malian communities: a prospective cohort study. Clin Infect Dis. 2022;74:1030–8. DOIPubMedGoogle Scholar
- Fryatt A, Simms V, Bandason T, Redzo N, Olaru ID, Ndhlovu CE, et al. Community SARS-CoV-2 seroprevalence before and after the second wave of SARS-CoV-2 infection in Harare, Zimbabwe. EClinicalMedicine. 2021;41:
101172 . DOIPubMedGoogle Scholar - Kleynhans J, Tempia S, Wolter N, von Gottberg A, Bhiman JN, Buys A, et al.; PHIRST-C Group. PHIRST-C Group. SARS-CoV-2 seroprevalence in a rural and urban household cohort during first and second waves of infections, South Africa, July 2020–March 2021. Emerg Infect Dis. 2021;27:3020–9. DOIPubMedGoogle Scholar
- World Health Organization. Seroepidemiological investigation protocol for coronavirus 2019 (COVID-19) infection [cited 2021 Nov 3]. https://www.who.int/publications/i/item/WHO-2019-nCoV-Seroepidemiology-2020.2
- Ayouba A, Thaurignac G, Morquin D, Tuaillon E, Raulino R, Nkuba A, et al. Multiplex detection and dynamics of IgG antibodies to SARS-CoV2 and the highly pathogenic human coronaviruses SARS-CoV and MERS-CoV. J Clin Virol. 2020;129:
104521 . DOIPubMedGoogle Scholar - Nkuba Ndaye A, Hoxha A, Madinga J, Mariën J, Peeters M, Leendertz FH, et al. Challenges in interpreting SARS-CoV-2 serological results in African countries. Lancet Glob Health. 2021;9:e588–9. DOIPubMedGoogle Scholar
- Lumley SF, Wei J, O’Donnell D, Stoesser NE, Matthews PC, Howarth A, et al.; Oxford University Hospitals Staff Testing Group. The duration, dynamics, and determinants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody responses in individual healthcare workers. Clin Infect Dis. 2021;73:e699–709. DOIPubMedGoogle Scholar
- Nkuba AN, Makiala SM, Guichet E, Tshiminyi PM, Bazitama Y, Yambayamba M, et al. High prevalence of anti-SARS-CoV-2 antibodies after the first wave of COVID-19 in Kinshasa, Democratic Republic of the Congo: results of a cross-sectional household-based survey. Clin Infect Dis. 2022;74:882–90. DOIPubMedGoogle Scholar
- The World Bank. Cameroon: world development indicators. 2019 [cited 2021 Nov 26]. https://data.worldbank.org/country/cameroon
- Mandolo J, Msefula J, Henrion MYR, Brown C, Moyo B, Samon A, et al. SARS-CoV-2 exposure in Malawian blood donors: an analysis of seroprevalence and variant dynamics between January 2020 and July 2021. BMC Med. 2021;19:303. DOIPubMedGoogle Scholar
Page created: April 03, 2022
Page updated: May 22, 2022
Page reviewed: May 22, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.